By Elric Langton | 21 February 2022
Investors of Synairgen Plc (LSE: SNG) were taught a brutal lesson today, and there have been a few of those among the small caps of late. The companyโs lead product, SNG001, underwent an international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19. Unfortunately, SNG001 did not meet its primaryโฆ